

This draft has not been adopted or endorsed by the European Commission. Any views expressed are the preliminary views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission. The information transmitted is intended only for the Member State or entity to which it is addressed for discussions and may contain confidential and/or privileged material.

COMMISSION IMPLEMENTING REGULATION (EU) .../...

of XXX

authorising the placing on the market of vitamin D₂ mushroom powder as a novel food and amending Implementing Regulation (EU) 2017/2470

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001¹, and in particular Article 12(1) thereof,

Whereas:

- (1) Regulation (EU) 2015/2283 provides that only novel foods authorised and included in the Union list of novel foods may be placed on the market within the Union.
- (2) Pursuant to Article 8 of Regulation (EU) 2015/2283, Commission Implementing Regulation (EU) 2017/2470² has established a Union list of novel foods.
- (3) On 14 December 2020, the company Luxidum GmbH ('the applicant') submitted an application for an authorisation to the Commission in accordance with Article 10(1) of Regulation (EU) 2015/2283 to place vitamin D₂ mushroom powder on the Union market as a novel food. The applicant requested for the novel food to be used in a number of foods intended for the general population. The applicant also requested the novel food to be used in food supplements as defined in Directive 2002/46/EC of the European Parliament and of the Council³ for excluding food supplements for infants, and in foods for special medical purposes as defined in Regulation (EU) No 609/2013

¹ OJ L 327, 11.12.2015, p. 1, ELI: <http://data.europa.eu/eli/reg/2015/2283/oj>.

² Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods (OJ L 351, 30.12.2017, p. 72, ELI: http://data.europa.eu/eli/reg_impl/2017/2470/oj).

³ Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements (OJ L 183, 12.7.2002, p. 51, ELI: <http://data.europa.eu/eli/dir/2002/46/oj>).

of the European Parliament and of the Council⁴, excluding foods for special medical purposes intended for infants.

- (4) On 14 December 2020, the applicant also made a request to the Commission for the protection of the following proprietary data: the production process⁵ and the stability tests, including the respective certificate of analysis⁶.
- (5) On 28 May 2021, the Commission requested the European Food Safety Authority ('the Authority') to carry out an assessment of vitamin D₂ mushroom powder as a novel food.
- (6) On 30 April 2024, the Authority adopted its scientific opinion on the 'Safety of vitamin D₂ mushroom powder as a Novel food pursuant to Regulation (EU) 2015/2283 (NF 2020/2226)'⁷ in accordance with Article 11 of Regulation (EU) 2015/2283.
- (7) In its scientific opinion, the Authority concluded that the novel food, vitamin D₂ mushroom powder, is safe under the proposed conditions of use.
- (8) In its scientific opinion, the Authority also noted that its conclusion on the safety of the novel food was based on the data concerning the production process and the stability tests, including the respective certificate analysis, without which it could not have assessed the novel food and reached its conclusion.
- (9) The Commission requested the applicant to further clarify the justification provided with regard to its proprietary claim over those data and studies and to clarify their claim to an exclusive right of reference to them in accordance with Article 26(2)(b) of Regulation (EU) 2015/2283.
- (10) The applicant declared that it held proprietary and exclusive rights of reference to the data on the production process and the stability tests, including the respective certificate analysis, at the time it submitted the application, and that third parties cannot lawfully access, use or refer to those data.
- (11) The Commission assessed all the information provided by the applicant and considered that it has sufficiently substantiated the fulfilment of the requirements laid down in Article 26(2) of Regulation (EU) 2015/2283. Therefore, data on the production process and the stability tests, including the respective certificate analysis, should be protected in accordance with Article 27(1) of Regulation (EU) 2015/2283. Accordingly, only the applicant should be authorised to place vitamin D₂ mushroom powder on the market within the Union during a period of five years from the entry into force of this Regulation.
- (12) However, restricting the authorisation of vitamin D₂ mushroom powder and the reference to the data contained in the applicant's file for their sole use does not prevent subsequent applicants from applying for an authorisation to place on the market the

⁴ Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009 (OJ L 181, 29.6.2013, p. 35, ELI: <http://data.europa.eu/eli/reg/2013/609/oj>).

⁵ Section of "3.2 Description of the production process".

⁶ Sections „4.3 Stability of vitamin D₂” and „4.4 Stability of NF as an ingredient in a representative processed food”.

⁷ EFSA Journal. 2024;22:e8817.

same novel food provided that their application is based on legally obtained information supporting such an authorisation.

- (13) A labelling requirement should be provided in order to properly inform the consumers that infants should not consume food supplements containing vitamin D₂ mushroom powder.
- (14) It is appropriate that the inclusion of vitamin D₂ mushroom powder as a novel food in the Union list of novel foods contains the information referred to in Article 9(3) of Regulation (EU) 2015/2283.
- (15) Vitamin D₂ mushroom powder be included in the Union list of novel foods set out in Implementing Regulation (EU) 2017/2470. The Annex to Implementing Regulation (EU) 2017/2470 should therefore be amended accordingly.
- (16) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

- (1) Vitamin D₂ mushroom powder is authorised to be placed on the market within the Union.
Vitamin D₂ mushroom powder shall be included in the Union list of novel foods set out in Implementing Regulation (EU) 2017/2470.
- (2) The Annex to Implementing Regulation (EU) 2017/2470 is amended in accordance with the Annex to this Regulation.

Article 2

Only the company Luxidum GmbH ⁸ is authorised to place on the market within the Union the novel food referred to in Article 1, for a period of 5 years from [*the date of entry into force of this Regulation*] [*OP please insert the date*], unless a subsequent applicant obtains an authorisation for that novel food without reference to the scientific data protected pursuant to Article 3 or with the agreement of Luxidum GmbH.

Article 3

The scientific data contained in the application file and fulfilling the conditions laid down in Article 26(2) of Regulation (EU) 2015/2283 shall not be used for the benefit of a subsequent applicant for a period of 5 years from the date of entry into force of this Regulation without the agreement of Luxidum GmbH.

Article 4

This Regulation shall enter into force on the twentieth day following that of its publication in *the Official Journal of the European Union*.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

⁸ Tempelhof 3, 74594 Kressberg, Germany.

Done at Brussels,

For the Commission
The President
Ursula VON DER LEYEN